Yale Cancer Center at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Yale Cancer Center brings 2 presentations to ASH 2026 in New Orleans. Its program centres on preventing and managing the intermediate and long-term side effects of CAR T, alongside targeted drugs for AML, MDS and CCUS. It also reviews delayed nerve and gut immune toxicities after CAR T for multiple myeloma.
| Organization | ASH 2026 Attendance |
|---|---|
Yale Cancer Center New Haven, CT | |
NCI-designated comprehensive cancer center of Yale School of Medicine, delivering patient care through Smilow Cancer Hospital in New Haven. | Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists. Talk Straight to the Point: Targeted Therapies in MDS and CCUS Which patients with myelodysplastic syndromes or clonal cytopenia of undetermined significance are most likely to benefit from targeted drugs. Talk A Practical Review of delayed Neurologic and Gastrointestinal Immune Toxicities After CAR-T Therapy in Multiple Myeloma Delayed nerve and gut side effects of CAR-T therapy for multiple myeloma, such as parkinsonism and colitis, and spotting and treating them early. Session Driving CARs Safely- Preventing and Managing Intermediate and Long-Term CAR-T Toxicity Later side effects of CAR-T therapy, including low blood counts, infections and immune problems, and how to monitor, prevent and treat them. |
Instantly find 20 buyers from Yale Cancer Center
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction